Glycoprotein IIb/IIIa Inhibitors for Heart Attack and Unstable Angina
| abciximab |
ReoPro |
| eptifibatide |
Integrilin |
| tirofiban |
Aggrastat |
These medicines prevent the formation of
blood clots. They can help prevent blood clots in the coronary arteries after a heart attack.
Glycoprotein IIb/IIIa inhibitors might be used with angioplasty after a heart attack. But they are not used for everyone.
Glycoprotein IIb/IIIa inhibitors may help certain people who have angioplasty after a heart attack, such as people who are at high risk for serious blood clots.
1
Glycoprotein IIb/IIIa inhibitors are given in the hospital. So a person is watched closely for any side effects.
Bleeding inside the body is the most common side effect.
See Drug Reference for a full list of side effects. (Drug
Reference is not available in all systems.)
Citations
-
Kushner KG, et al. (2009). 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevated myocardial infarction (Updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (Updating the 2005 guideline and 2007 focused update). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 120(22): 2271–2306.
|
By
| Healthwise Staff |
|
Primary Medical Reviewer
| Kathleen Romito, MD - Family Medicine |
|
Primary Medical Reviewer
| E. Gregory Thompson, MD - Internal Medicine |
|
Specialist Medical Reviewer
| Stephen Fort, MD, MRCP, FRCPC - Interventional Cardiology |
|
Last Revised
| April 29, 2011 |
Last Revised:
April 29, 2011
Kushner KG, et al. (2009). 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevated myocardial infarction (Updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (Updating the 2005 guideline and 2007 focused update). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 120(22): 2271–2306.
